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There is a clinical imperative to improve metabolic control in the treatment of patients with type 1 diabetes, but in
doing so, hypoglycemia should be avoided at all costs. Insulin analogues and the assumption they would better
mimic the pharmacokinetic profile of endogenous insulin secretion emerged as a magic bullet in the treatment of
patients with type 1 diabetes. However, although insulin analogues have pharmaceutical properties, such as
pharmacodynamic stability, reproducibility of action, and a more physiological timing of action, which could
possibly facilitate insulin use, the results obtained in clinical practice have not been as good as expected. Like all
clinical decisions, the decision regarding which insulin would be better for the patient should be, if possible,
evidence based. Here, we briefly discuss evidence for the use of insulin analogues and the different views with
respect to the available evidence that lead to different interpretations and decisions regarding the use of this new
technology.Background
Compared with the general population, at age 20 years,
life expectancy in patients with type 1 diabetes is shorter
by approximately 11 years for men and 13 years for
women [1]. Early in life, excess mortality is explained by
diabetic ketoacidosis and hypoglycemia; later, cardiovas-
cular diseases are the main cause. However, intensive
treatment is probably able to amend the chances of sur-
vival, as has been shown in the long-term follow-up of the
Diabetes Control and Complications Trial (DCCT): after 27
years, mortality was significantly lower among those who
had received intensive vs. conventional therapy [2].
The results of the DCCT drove the need to attain lower
glucose levels to achieve an HbA1c of 7.0%. Nevertheless,
strict glycemic control is associated with a higher incidence
of hypoglycemia, an undesired and harmful side effect of
treatment [3], which, by itself, can lead to fear, anxiety,
poor sleep quality, loss of work productivity, impaired
functioning the following day, and treatment nonadher-
ence [4-6]. Paradoxically, nonadherence is linked to worse* Correspondence: beatrizschaan@gmail.com
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article, unless otherwise stated.glycemic control, hypoglycemia and all-cause mortality
[7,8]. Additionally, any form of hypoglycemia has a nega-
tive impact on quality of life, especially nocturnal and/or
severe hypoglycemia [9,10].
Therefore, improved metabolic control needs to be ac-
complished while avoiding hypoglycemia, since diabetes
management that minimizes hypoglycemia while main-
taining good glycemic control would positively affect
clinical outcomes, with the best result for the patient,
the doctor, and the healthcare system. Great advances
have been made over the last century in terms of the
technologies available to treat diabetes, with glucose
measurement devices, insulin pens, insulin pumps and
modified insulins, among others, providing the possibility
of greater metabolic control with fewer hypoglycemic epi-
sodes and better quality of life. Nevertheless, poor access
to those technologies, especially among low and middle-
income countries, remains the rule [11].
Here, we briefly discuss evidence for the use of insulin
analogues and the different views with respect to the
available evidence that lead to different interpretations
and decisions regarding the use of this new technology.Central. This is an Open Access article distributed under the terms of the
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A few years after the first insulin preparations were
launched on the market, long-acting insulins were devel-
oped (NPH, lente and ultralente insulins) and later animal
insulins were replaced by biosynthetic human insulins.
Long-acting insulins allowed patients to be treated with
one or two daily injections, but because of their slow and
erratic absorption, delayed clearance, and unstable basal
plasma levels, hyperglycemia and hypoglycemic peaks were
common with their use [12]. Genetically modified insulins
(lispro, aspart, glargine and detemir) became available 50
years later [13]. Since their launch, the use of insulin ana-
logues has steadily increased [14]. Insulin analogues more
closely mimic the pharmacokinetic profile of endogenous
insulin, leading to the widespread assumption that they
would substantially improve the treatment of patients with
type 1 diabetes. Modern insulin regimens focus on main-
taining stable basal insulin levels (basal) while reducing
post-prandial glucose excursions by using rapid-acting in-
sulins (bolus) whenever necessary, in an effort to mimic
the secretion pattern of endogenous insulin [15]. However,
although insulin analogues have pharmaceutical proper-
ties, such as pharmacodynamic stability, reproducibility of
action, and a more physiological timing of action, that
may facilitate insulin use, the results obtained in random-
ized controlled trials (RCTs) and systematic reviews of
RCTs have not been as good as originally expected.
Like all clinical decisions, the decision regarding which
insulin would be better for the patient should be evidence-
based. The first step in evidence-based medicine is to
search for studies that answer a clinical question. Once
obtained, the evidence needs to be critically examined and
then, once accepted, finally, integrated with the physician’s
clinical expertise and the patient’s preferences and values.
Randomized controlled trials and systematic reviews of
RCTs are the gold standard tools for evaluating interven-
tions [16]. Systematic reviews that included RCTs per-
formed in type 1 diabetic patients comparing human
insulins (NPH or regular) with insulin analogues (long-
acting or short-acting) failed to show any important clin-
ical benefit considering HbA1c as the outcome [17-24].
However, in the same studies, reductions in severe and
nocturnal hypoglycemia were found, especially with short-
acting insulin analogues as compared to regular insulin
and detemir as compared to NPH. These findings should
be viewed with caution since none of the studies was
blinded and most of them are of low-moderate quality and
were funded by the pharmaceutical industry. Furthermore,
throughout the studies, hypoglycemia was treated as a sec-
ondary endpoint and different definitions were applied.
It is also important to note that most of the patients
selected to participate in these trials were not those who
would most benefit from insulin analogues. Ideally, the
candidates for such trials should be patients with type 1diabetes, who have tried all strategies to attain good
metabolic control with acceptable rates of hypoglycemia,
including frequent glucose monitoring, adjusting insulin
dosages according to changes in meals and exercise, and
who have been followed closely by a healthcare team.
Moreover, patients with a high risk of hypoglycemia, es-
pecially severe and nocturnal hypoglycemia, would be
more likely to benefit [7]. Unfortunately, such patients
are often excluded from RCTs. To date, only one RCT
has been conducted in this subgroup of patients at high
risk for hypoglycemia, with hypoglycemia as the primary
endpoint. It found that patients randomized to the treat-
ment with insulin analogues (detemir and aspart) experi-
enced less hypoglycemia than those randomized to
treatment with human insulins (NPH and regular) [25].
These data can be interpreted in several ways depend-
ing on the perspective of the observer, who may take a:
passionate, biased, strict or pragmatic view – we include
ourselves in the latter group. Passionate eyes have faith
in what they believe irrespective of any diversion, scien-
tific or otherwise, from the first impression. Biased eyes
are those influenced by other interests. Clearly, a com-
monplace example of this view is the influence the
pharmaceutical industry has on professional judgment in
many medical decisions [26,27]. In general, these two
patterns of interpretation would tend to view insulin
analogues as being superior to human insulins. A strict
interpretation is one in which only evidence, in the very
strict sense of the word, is taken into account. No con-
cessions are made, and the evidence is applicable only to
those patients that are similar to those included in the
RCTs published. Lastly, but no less importantly, there is
the pragmatic view, which suggests that because the
published RCTs do not answer all our clinical questions,
the physician needs to apply his/her experience. While
insulin analogues may or may not be better than human
insulins, clinical practice (the specialist opinion) clearly
shows they provide great benefits, especially and maybe
only for the small percentage of patients that experience
frequent, severe or nocturnal hypoglycemia. Such pa-
tients might be prevented from achieving greater meta-
bolic control because their glucose levels cannot be
brought down due to episodes of hypoglycemia that pre-
clude them from achieving optimal metabolic control.
Under these exceptional circumstances, common sense
might be applied when considering the potential risks
and benefits of interventions. The example is the classic
one of the need for a control group to test the efficacy
of using a parachute after jumping from an airplane
[28]. If no RCT has been carried out among patients in
circumstances sufficiently similar to those of our pa-
tient/s, we must look for the next best evidence and
work from there. This should be called “clinical-signifi-
cance based medicine”.
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their high cost, evidence based medicine, the needs of
patients and the ability of the healthcare system to pay
for them democratically. The UK National Institute for
Health and Care Excellence (NICE) and the Pharmaceutical
Management Agency (PHARMAC) in New Zealand have
recommended human insulins as first line therapy, but
insulin analogues can be prescribed under specific circum-
stances, as an option for those patients with type 1 diabetes
whose lifestyle is significantly restricted by recurrent symp-
tomatic hypoglycemic episodes [29,30]. In Brazil, only a few
states provide insulin analogues for patients with type 1 dia-
betes under multiple and varying criteria [31]. This system
generates inequalities, as patients with the same clinical
condition may or may not receive the benefit from the
healthcare system depending on the state they live in. This
is not in accordance with the principles of the Brazilian
Public Healthcare System. Curiously, although insulin ana-
logues are twice the price of human insulins in other coun-
tries, in Brazil glargine and detemir are 377% and 536%
more expensive than human insulins, respectively [14,32].
Interestingly, two Brazilian states, Rio Grande do Sul and
Minas Gerais, have protocols to indicate the use of the
analogue glargine. In these two states the total population
with type 1 diabetes is estimated to be 241000 subjects and
only 5572 (2.31%) of whom meet the inclusion criteria for
glargine use and are receiving this analogue.
Furthermore, there is a need to recognize that, by
themselves, new technologies are certainly insufficient
to ensure the goals related to diabetes are achieved.
Education and support from healthcare professionals,
patients and families are all-important, and may well be
cheaper, and perhaps more effective in achieving better
long-term outcomes [33,34]. Suboptimal control may
be associated with social difficulties, inadequate food
intake and mainly non-adherence to insulin plans
[13,35]. There is an urgent need to invest in actions to
improve these issues.
Conclusion
In conclusion, we suggest adopting a pragmatic view of
the evidence when considering the best treatment for
patients with type 1 diabetes in order to achieve the lowest
HbA1c with the lowest rate of hypoglycemia. We also sug-
gest use, not only the concepts of evidence-based medi-
cine but also of “clinical-significance based medicine”. In
our opinion, clearly, while treatment with insulin ana-
logues should not be interpreted as a magic bullet (pas-
sionate view), there is no need to wait for the perfect
study to appear in order to decide to prescribe these drugs
to a subgroup of patients. When recommending their use,
the capacity of the healthcare system to provide it to all
subjects with the same disease, without inequalities, must
be considered. Protocols for wisely choosing those patientswho would most probably benefit from insulin analogues
are available and should guide Brazilian physicians in their
prescription [36]. The equation is not simple, and all
actors involved should work to achieve a proper balance.
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